Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results
An erratum to this article was published (J Clin Endocrinol Metab, 7 Oct 2026 ↗)
Primary result · Change in trunk percent fatResult — go to the resultLS mean difference −2.04 %Authors' conclusion
The foresiGHt trial met its primary efficacy end point by demonstrating superiority of lonapegsomatropin vs placebo with similar safety and tolerability, supporting its potential as a once-weekly treatment option for adults with GHD.
Study context
- Population
- Adults with GHD, 116 centers in North America, Europe and Asia-Pacificrandomized 1:1:1
- Participants
- 259 adults
- Comparison
- Once-weekly lonapegsomatropin vs placebo
- Primary endpoint
- Change from baseline in trunk percent fat
- Follow-up
- Week 38
Methodological detailsmulticenter, parallel-arm, placebo-controlled (double-blind), active-controlled (open-label)
- Multicenter
- Parallel-arm
- Placebo-controlled (double-blind)
- Active-controlled (open-label)
Primary result
Change in trunk percent fat
LS mean difference
−2.04 %
P < 0.001
Change by group
Lonapegsomatropin
−1.68
%
Placebo
+0.37
%
As reported in the abstract
Secondary outcomes
kg
| Outcome | Lonapegsomatropin | Placebo | LS mean difference (kg) | P value |
|---|---|---|---|---|
| Change in total body lean mass · week 38Lonapegsomatropin vs Placebo | +1.60 | −0.11 | 1.70 | P < 0.0001 |
| Change in trunk fat mass · week 38Lonapegsomatropin vs Placebo | −0.48 | +0.22 | −0.70 | P = 0.0053 |
Safety
- Safety and tolerability profile of lonapegsomatropin comparable to somatropin
Original publication
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results. J Clin Endocrinol Metab. Published 20 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →